New combo therapy targets rare salivary gland cancer
Disease control
Recruiting now
This study tests a combination of hormone therapy (goserelin) and an immunotherapy drug (pembrolizumab) in 20 people with advanced salivary gland cancer that cannot be removed by surgery or radiation. The goal is to see if the treatment shrinks tumors or slows the disease. Partic…
Phase: PHASE2 • Sponsor: Manish Patel • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC